Podchaser Logo
Home
The Science of Clinical Trials with Cardinal Health

The Science of Clinical Trials with Cardinal Health

Released Thursday, 31st August 2023
Good episode? Give it some love!
The Science of Clinical Trials with Cardinal Health

The Science of Clinical Trials with Cardinal Health

The Science of Clinical Trials with Cardinal Health

The Science of Clinical Trials with Cardinal Health

Thursday, 31st August 2023
Good episode? Give it some love!
Rate Episode

In this episode, host Shikha Jain, MD, speaks with Cardinal Health’s Parisa Asgarisabet, PhD and Scott Swain, PhD, MPH about benefits and uses of real-world evidence, the issue of diversity in clinical trials and more.

•    Welcome to another exciting episode of Oncology Overdrive 1:11
•    About Swain 1:26
•    About Asgarisabet 2:45
•    The interview 3:30
•    About Swain and how you ended up at Cardinal Health 3:50
•    About Asgarisabet’s journey and how she ended up at Cardinal Health 5:09
•    What is Cardinal Health and why should people know about the work they are doing? 6:37
•    How is the work Cardinal Health is doing directly applicable to practicing oncologists?  7:30 
•    Jain, Asgarisabet, and Swain on Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End Results (SEER) cancer patient registry data in advanced renal cell carcinoma (aRCC). 10:32
•    How can we scale real world data in a bigger way and make this the standard as opposed to the exception? 14:02 
•    Jain and Swain on diversity, equity, and inclusion in the clinical trials design space 17:57
•    Asgarisabet and Swain on the economic implications of a lack of diversity in clinical trials 19:53
•    Swain and Jain on the importance of community engagement and outreach in achieving diversity of backgrounds in clinical trials 24:42
•    What do you think are the next steps to implement real world data in order to make a larger impact? 27:38
•    Should real world data be used in concert with randomized controlled trials or should this data be used independently? 29:02
•    When we talk about these types of transformation in how we look at diseases and deciding the best plan of action, do you anticipate there being a challenge with insurance companies approving treatments using real world data? 30:27
•    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 35:18
•    How to contact Swain and Asgarisabet 37:57
•    Thanks for listening 39:13

Scott Swain, PhD, MPH is a Director of Regulatory Science and Real-world Evidence with Cardinal Health.

Parisa Asgarisabet, PhD is a Lead statistician in the Real-World Evidence & Insights team at Cardinal Health.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Asgarisabet can be reached via LinkedIn or via email [email protected]. Swain can be reached via LinkedIn or via email [email protected].

Disclosures:  Jain reports no relevant financial disclosures. Asgarisabet and Swain are employees and shareholders of Cardinal Health.

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features